Cargando…

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis

Background:We conducted this pooled analysis to investigate the impact of RECIST 1.1 on the selection of target lesions and classification of tumor response, in comparison with RECIST 1.0. Methods: We searched MEDLINE and EMBASE for articles with terms of RECIST 1.0 or RECIST 1.1. We looked into all...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jung Han, Min, Seon Jeong, Jang, Hyun Joo, Cho, Ji Woong, Kim, Soo Ho, Kim, Hyeong Su
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349880/ https://www.ncbi.nlm.nih.gov/pubmed/25767610 http://dx.doi.org/10.7150/jca.11316

Ejemplares similares

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review
por: Min, Seon Jeong, et al.
Publicado: (2016)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
por: Iannessi, Antoine, et al.
Publicado: (2021)

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
por: Zheng, Bingjie, et al.
Publicado: (2021)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis
por: Kim, Hong Deok, et al.
Publicado: (2019)

Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer
por: Kim, In-Ho, et al.
Publicado: (2018)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
por: Xu, Ying, et al.
Publicado: (2022)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yu, Hongli, et al.
Publicado: (2022)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
por: Beaumont, Hubert, et al.
Publicado: (2023)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
por: Beaver, Julia A., et al.
Publicado: (2018)

Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0
por: Kitajima, Kazuhiro, et al.
Publicado: (2018)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1
por: Muenzel, Daniela, et al.
Publicado: (2012)

The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria
por: Reginelli, Alfonso, et al.
Publicado: (2023)

Evaluation of the capability and reproducibility of RECIST 1.1. measurements by technologists in breast cancer follow-up: a pilot study
por: Gouel, Pierrick, et al.
Publicado: (2023)

Imaging beyond RECIST: CT and MRI in molecular therapies
por: Diederich, Stefan
Publicado: (2012)

Response assessment in daily practice: RECIST and its modifications
por: Sohaib, Aslam
Publicado: (2014)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
por: Ko, Ching-Chung, et al.
Publicado: (2021)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma
por: RUAN, MAOMEI, et al.
Publicado: (2013)

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
por: Luo, Yanji, et al.
Publicado: (2017)

Breaking down the RECIST 1.1 double read variability in lung trials: What do baseline assessments tell us?
por: Iannessi, Antoine, et al.
Publicado: (2023)

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study
por: Toffart, Anne-Claire, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ov8bnv7ed3715erki8806capvd